• RIPostC, Ketone Bodies, and Ferroptosis After Stroke

  2026-08-23

  A 2024 ACS Chemical Neuroscience study identifies ketone body metabolism as a mechanistic link between remote ischemic postconditioning and reduced ferroptotic injury after ischemic stroke. Using rat middle cerebral artery occlusion and oxygen-glucose deprivation/reoxygenation models, the researchers connect improved energy metabolism, preserved GPX4, reduced ACSL4, and lower iron burden with neuroprotection.

• N2-Alkyl-dG Lesions Drive R-Loop Accumulation

  2026-08-22

  Wang and colleagues show that minor-groove N2-alkyl-dG lesions promote R-loop accumulation in chromatin and plasmid DNA, linking DNA alkylation to transcriptional obstruction and genome instability. By combining imaging, R-loop sequencing, transcriptional analyses, and helicase depletion, the study provides a mechanistic framework for understanding how unrepaired alkylated guanine lesions alter nucleic acid metabolism.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-08-21

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as a transferable regulator of macrophage behavior in hepatocellular carcinoma. Its data connect SNORD52 uptake by THP-1 macrophages with M2 polarization and increased JAK2/STAT6 pathway activity, providing a mechanistic framework for studying tumor–immune communication.

• Rapakinin Links PGI₂–IP to CCK1 Vasorelaxation

  2026-08-20

  The reference study identified rapakinin, the Arg-Ile-Tyr peptide from rapeseed protein, as an endothelium-dependent vasorelaxant in mesenteric arteries from spontaneously hypertensive rats. Pharmacological experiments showed that its antihypertensive activity depends mainly on a prostaglandin I₂–IP receptor pathway followed by CCK1 receptor signaling, rather than on nitric oxide or bradykinin B2 receptor activation.

• Fe3O4@ZIF-8 Nanoparticles for Jaw Osteomyelitis

  2026-08-20

  The reference study presents Fe3O4@ZIF-8 core–shell nanoparticles as a dual-function platform for treating jaw osteomyelitis through pH-responsive Zn2+ release, bacterial stress sensitization, and magnetically assisted bone regeneration. Its main translational significance is the integration of infection control and bone repair in one material system, although detailed dosing, safety, and clinical validation remain necessary.

• GW 4869 in Lupus Nephritis Exosome Causality

  2026-08-19

  GW 4869 is more than an exosome release inhibitor: it is a causal perturbation tool for testing how podocyte-derived vesicles injure glomerular endothelial cells in lupus nephritis. This guide connects N-SMase biology, HMGB1 cargo analysis, assay controls, and practical handling of GW 4869 hydrochloride hydrate.

• Irinotecan (CPT-11) in Tumor–Stroma Translation

  2026-08-19

  Irinotecan and its active metabolite SN-38 provide a mechanistic bridge between DNA damage biology and patient-relevant model development. This thought-leadership guide explains how to move from colorectal cancer cell line inhibition to organoid, assembloid, and xenograft strategies while preserving interpretability, formulation control, and translational discipline.

• IL-12 mRNA and the Extrahepatic Delivery Frontier

  2026-08-18

  IL-12 mRNA is becoming a strategic tool for studying localized immune activation, but its translational value depends on more than transcript design. This article connects the engineered features of EZ Cap™ Mouse IL-12 mRNA (m1Ψ) with emerging extrahepatic delivery systems, experimental validation, and practical decision-making for immunotherapy research mRNA programs.

• Pifithrin-α: p53 Inhibition in Ferroptosis Assays

  2026-08-18

  Pifithrin-α (PFTα) provides a practical way to test whether p53 signaling contributes to apoptosis, growth arrest, or ferroptosis-associated injury. This guide translates a recent deltamethrin neurotoxicity study into reproducible cell-assay workflows, controls, optimization steps, and interpretation safeguards.

• Phosphatase Inhibitor Cocktail 1 in HPV Signaling

  2026-08-17

  Phosphatase Inhibitor Cocktail 1 can protect phosphorylation-dependent readouts in HPV-associated cancer research. This article connects phosphatase control with BET-driven signaling heterogeneity and shows how better sample preservation improves assay interpretation without overstating pathway causality.

• CD38 CAR Binder Structure and Affinity Tuning

  2026-08-17

  Cheng et al. structurally distinguish two CD38-targeting CAR binders, RP02 and 028, showing that epitope geometry can control enzymatic inhibition as well as receptor affinity. The study supports rationally attenuated CAR design as a way to reduce fratricide while preserving antitumor cytotoxicity, and it provides a framework for interpreting cell-death measurements in engineered T-cell studies.

• Luminescent ATP Detection Assay Kit for GBM

  2026-08-16

  Learn how the Luminescent ATP Detection Assay Kit can translate PXDN–LDHA glycolytic biology into a robust ATP endpoint for glioblastoma research. This guide focuses on assay interpretation, matrix-aware workflow design, normalization, and the limits of using ATP as a surrogate for metabolic flux.

• Phalloidin B7678: Fixed-Cell F-Actin Workflow

  2026-08-15

  Phalloidin (SKU B7678) is a high-affinity F-actin-binding cyclic heptapeptide toxin for stabilizing filament architecture in fixed, permeabilized cells, tissue sections, and cell-free assays. This guide covers dossier-listed parameters and QC practices; it should not be used for live-cell imaging or experiments requiring reversible cytoskeletal dynamics.

• Irinotecan and the Gut–Liver Axis in Steatohepatitis

  2026-08-14

  The reference study identifies intestinal barrier failure, lipopolysaccharide translocation, and excessive neutrophil extracellular trap formation as a mechanistic chain linking CPT-11 exposure to chemotherapy-induced steatohepatitis. Its findings position fucoidan-mediated barrier preservation and NETs suppression as investigational strategies for reducing irinotecan-associated liver injury without treating hepatotoxicity as an isolated hepatic event.

• Dual PI3K–AKT–ERK Blockade in Gefitinib Resistance

  2026-08-14

  Deng and colleagues developed a rational dual-drug nanoplatform to address gefitinib resistance and metastatic behavior in lung adenocarcinoma. By combining pathway analysis, synergy testing, phospho-proteomics, cellular models, xenografts, and zebrafish experiments, the study links coordinated PI3K–AKT and ERK inhibition with improved antitumor activity.

8412 records 1/561 page Next 12345 下5页 Last page